

### HCV Genotype Testing Prior to Treatment

---

*This measure is to be reported for all patients aged 18 years and older with chronic hepatitis C — a minimum of **once** per reporting period. This measure addresses a process that must occur prior to initiating antiviral treatment and should also be reported with Measure #84: RNA Testing Before Initiating Treatment.*

#### Measure description

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom HCV genotype testing was performed prior to initiation of antiviral treatment

#### What will you need to report for each patient with chronic hepatitis C for this measure?

If you select this measure for reporting, you will report:

- Whether or not the patient is receiving antiviral treatment for hepatitis C

If the patient is receiving antiviral treatment for hepatitis C, you will then need to report:

- Whether or not you performed HCV genotype testing prior to initiation of antiviral treatment

#### What if this process or outcome of care is not appropriate for your patient?

Some measures provide an opportunity for the physician or eligible health professional to document when a process or outcome of care is not appropriate for a given patient (also called performance exclusions). Because this measure is applicable to most if not all patients, there are no allowable performance exclusions.